The FDA approved the use of Johnson & Johnson's Sirturo, or bedaquiline, in combination with other drugs, to treat patients with multidrug-resistant tuberculosis. Sirturo, developed by J&J's Janssen Therapeutics, is the first new tuberculosis drug to gain approval in 40 years. Because of the possibility of fatal heart problems, Sirturo will carry a boxed warning.
J&J's tuberculosis drug Sirturo wins FDA approval
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||